PMID- 35123621
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220208
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 30
IP  - 1
DP  - 2022 Feb
TI  - [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].
PG  - 166-169
LID - 10.19746/j.cnki.issn.1009-2137.2022.01.027 [doi]
AB  - OBJECTIVE: To analyze the characteristics of gene mutation and overexpression in 
      newly diagnosed multiple myeloma (NDMM) patients. METHODS: Bone marrow cells from 
      208 NDMM patients were collected and analyzed. The gene mutation of 28 genes and 
      overexpression of 6 genes was detected by DNA sequencing. Chromosome structure 
      abnormalities were detected by fluorescence in situ hybridization (FISH). 
      RESULTS: Gene mutations were detected in 61 (29.33%) NDMM patients. Some 
      mutations occurred in 5 or more cases, such as NRAS, PRDM1, FAM46C, MYC, CCND1, 
      LTB, DIS3, KRAS, and CRBN. Overexpression of six genes (CCND1, CCND3, BCL-2, 
      CCND2, FGFR3, and MYC) were detected in 83 (39.9%) patients, and cell cycle 
      regulation gene was the most common. Single nucleotide polymorphisms (SNP) 
      changes were detected in 169 (81.25%) patients, the TP53 P72R gene SNP (70.17%) 
      was the most common. Abnormality in chromosome structure was correlated to gene 
      overexpression. Compared to the patients with normal chromosome structure, 
      patients with 14q32 deletion showed higher proportion of CCND1 overexpression. 
      Similarly, patients with 13q14 deletion showed higher proportion of FGFR3 
      overexpression, whereas patients with 1q21 amplification showed higher proportion 
      of CCND2, BCL-2 and FGFR3 overexpression. CONCLUSION: There are multiple gene 
      mutations and overexpression in NDMM. However, there is no dominated single 
      mutation or overexpression of genes. The most common gene mutations are those in 
      the RAS/MAPK pathway and the genes of cyclin family CCND are overexpression.
FAU - Fan, Yi
AU  - Fan Y
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Wang, Shu-Juan
AU  - Wang SJ
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Liu, Yan-Fang
AU  - Liu YF
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China,E-mail: fccliuyf1@zzu.edu.cn.
FAU - Wang, Chong
AU  - Wang C
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Li, Ya-Fei
AU  - Li YF
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Wang, Wei-Qiong
AU  - Wang WQ
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Hao, Qian-Qian
AU  - Hao QQ
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Zhang, Dan-Feng
AU  - Zhang DF
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Li, Ying-Mei
AU  - Li YM
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Sun, Hui
AU  - Sun H
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Guo, Rong
AU  - Guo R
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Chen, Shao-Qian
AU  - Chen SQ
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Xie, Xin-Sheng
AU  - Xie XS
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Li, Tao
AU  - Li T
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Wan, Ding-Ming
AU  - Wan DM
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
FAU - Jiang, Zhong-Xing
AU  - Jiang ZX
AD  - Department of Hematology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, Henan Province, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
SB  - IM
MH  - Chromosome Aberrations
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Multiple Myeloma/genetics
MH  - Mutation
OTO - NOTNLM
OT  - DNA sequencing
OT  - gene mutation
OT  - gene overexpression
OT  - multiple myeloma
EDAT- 2022/02/07 06:00
MHDA- 2022/02/09 06:00
CRDT- 2022/02/06 20:26
PHST- 2022/02/06 20:26 [entrez]
PHST- 2022/02/07 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
AID - 1009-2137(2022)01-0166-04 [pii]
AID - 10.19746/j.cnki.issn.1009-2137.2022.01.027 [doi]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):166-169. doi: 
      10.19746/j.cnki.issn.1009-2137.2022.01.027.